Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
George C. Tsokos, M.D., Chief of the Rheumatology Division at Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School, has been selected as the 2015 recipient of the Lupus Insight Prize.
LFA-REAL aims to improve health and quality of life for people with lupus.
People with lupus need and deserve a full arsenal of treatments. With many new and innovative drugs for lupus in the drug pipeline, these highly anticipated treatments will mean nothing if people with lupus cannot afford them.
Statement from Sandra C. Raymond, President and CEO of the Lupus Foundation of America
Foundation-funded research studies highlighted at premier rheumatology meeting in Boston.
Award is the largest amount allocated to lupus since 2006